ArticleProceedings of the National Academy of Sciences of the United States of America2019
Multipotent fetal-derived Cdx2 cells from placenta regenerate the heart.
Article in Proceedings of the National Academy of Sciences of the United States of America, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 24 citations in OpenAlex.
- Microchimerism: The Hidden Cellular Dialogue Between Mother and Fetal That Shapes Lifelong Immunity.Expert reviews in molecular medicine · 2026Review
- CDX2 Promotes Hepatic Specification of hiPSC-derived Endoderm Through the PI3K-Akt-GSK3β Pathway for Improved Therapeutic Efficacy.Stem cell reviews and reports · 2026Article
- Therapeutic impact of human trophoblast stem cells in peritoneal and pneumonia-induced sepsis in mice.Stem cell research & therapy · 2025Article
- Analyzing the relationship of RNA and DNA methylation with gene expression.Genome biology · 2025Article
- The when, what, and where of naturally-acquired microchimerism.Seminars in immunopathology · 2025Review
- Leveraging chromatin state transitions for the identification of regulatory networks orchestrating heart regeneration.Nucleic acids research · 2024Article
- Presence of fetal microchimerisms in the heart and effect on cardiac repair.Frontiers in cell and developmental biology · 2024Article
- Functional antagonism between ΔNp63α and GCM1 regulates human trophoblast stemness and differentiation.Nature communications · 2022Article
- Regulation of maternal-fetal metabolic communication.Cellular and molecular life sciences : CMLS · 2021Review
- Side-Population Trophoblasts Exhibit the Differentiation Potential of a Trophoblast Stem Cell Population, Persist to Term, and are Reduced in Fetal Growth Restriction.Stem cell reviews and reports · 2020Article
- Clinical-based Cell Therapies for Heart Disease-Current and Future State.Rambam Maimonides medical journal · 2020Review
- Multipotency of mouse trophoblast stem cells.Stem cell research & therapy · 2020Article
- Cardiopoietic stem cell therapy restores infarction-altered cardiac proteome.NPJ Regenerative medicine · 2020Article
- Recent advances in myocardial regeneration strategy.The Journal of international medical research · 2019Review
- Placental stem cells can regenerate the heart.Nature reviews. Cardiology · 2019Article
Corrections and comments
- Commented on by
Authors and funding
9 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The extremely limited regenerative potential of adult mammalian hearts has prompted the need for novel cell-based therapies that can restore contractile function in heart disease. We have previously shown the regenerative potential of mixed fetal cells that were naturally found migrating to the injured maternal heart. Exploiting this intrinsic mechanism led to the current hypothesis that Caudal-type homeobox-2 (Cdx2) cells in placenta may represent a novel cell type for cardiac regeneration. Using a lineage-tracing strategy, we specifically labeled fetal-derived Cdx2 cells with enhanced green fluorescent protein (eGFP). Cdx2-eGFP cells from end-gestation placenta were assayed for cardiac differentiation in vitro and in vivo using a mouse model of myocardial infarction. We observed that these cells differentiated into spontaneously beating cardiomyocytes (CMs) and vascular cells in vitro, indicating multipotentiality. When administered via tail vein to infarcted wild-type male mice, they selectively and robustly homed to the heart and differentiated to CMs and blood vessels, resulting in significant improvement in contractility as noted by MRI. Proteomics and immune transcriptomics studies of Cdx2-eGFP cells compared with embryonic stem (ES) cells reveal that they appear to retain "stem"-related functions of ES cells but exhibit unique signatures supporting roles in homing and survival, with an ability to evade immune surveillance, which is critical for cell-based therapy. Cdx2-eGFP cells may potentially represent a therapeutic advance in allogeneic cell therapy for cardiac repair.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.